StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) stock

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.51+0.04 (+0.24%)

Close on Nov 18, 2026Market cap $3.62BP/E –Yield –

Relay Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Relay Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$310.44M. For fiscal 2025 it was -$302.74M. The highest annual figure on record is -$55.80M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$302.74M–
FY2024Dec 31, 2024-$372.47M–
FY2023Dec 31, 2023-$373.00M–
FY2022Dec 31, 2022-$299.28M–
FY2021Dec 31, 2021-$364.70M–
FY2020Dec 31, 2020-$55.80M–
FY2019Dec 31, 2019-$84.05M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$90.82M–
Q1 FY2026Mar 31, 2026-$78.59M–
Q4 FY2025Dec 31, 2025-$60.63M–
Q3 FY2025Sep 30, 2025-$80.39M–
Q2 FY2025Jun 30, 2025-$76.85M–
Q1 FY2025Mar 31, 2025-$84.87M–
Q4 FY2024Dec 31, 2024-$84.98M–
Q3 FY2024Sep 30, 2024-$96.37M–
Q2 FY2024Jun 30, 2024-$100.76M–
Q1 FY2024Mar 31, 2024-$90.36M–
Q4 FY2023Dec 31, 2023-$92.20M–
Q3 FY2023Sep 30, 2023-$73.58M–
Q2 FY2023Jun 30, 2023-$106.05M–
Q1 FY2023Mar 31, 2023-$101.18M–
Q4 FY2022Dec 31, 2022-$72.85M–
Q3 FY2022Sep 30, 2022-$85.89M–
Q2 FY2022Jun 30, 2022-$77.81M–
Q1 FY2022Mar 31, 2022-$62.72M–
Q4 FY2021Dec 31, 2021-$67.72M-293.6%
Q3 FY2021Sep 30, 2021-$60.99M–
Q2 FY2021Jun 30, 2021-$193.58M–
Q1 FY2021Mar 31, 2021-$42.41M–
Q4 FY2020Dec 31, 2020$34.99M–
Q3 FY2020Sep 30, 2020-$36.61M–
Q2 FY2020Jun 30, 2020-$27.72M–
Q1 FY2020Mar 31, 2020-$26.46M–
Q4 FY2019Dec 31, 2019-$25.83M–
Q3 FY2019Sep 30, 2019-$21.91M–
Q2 FY2019Jun 30, 2019-$19.91M–

More Relay Therapeutics figures

See a number that looks wrong?